NEW YORK (360Dx) – Akers Biosciences this week reported 2016 revenues of $3 million, up 40 percent from $2.1 million in 2015, driven by an 85 percent year-over-year increase in sales of its heparin allergy test.

The firm reported a net loss of $3.3 million, or $0.61 per share, down 65% from a loss of $9.3 million, or $1.81 per share, in 2015.

Its R&D expenses were $1.2 million, down 15 percent from $1.4 million in 2015, and its SG&A expenses were $5.1 million, down 22 percent from $6.5 million in the prior year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.